Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Jean Torrisi"'
Autor:
Romel Somwar, Alexander Drilon, Marc Ladanyi, Eileen M. O'Reilly, Elisa de Stanchina, Ernesto Wasserman, Jeroen J. Lammerts van Bueren, Ron C.J. Schackmann, Cecile A.W. Geuijen, Marie N. O'Connor, Jim Ford, Jean Torrisi, Thrusha Chauhan, Sara H. Shameem, Morana Vojnic, Allan J.W. Lui, Marissa S. Mattar, Whitney J. Sisso, Inna Khodos, Madelyn Espinosa-Cotton, Igor Odintsov, Alison M. Schram
Supplementary Figure from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::957edba211dae8e33116bb0bbf5e53e7
https://doi.org/10.1158/2159-8290.22541186.v1
https://doi.org/10.1158/2159-8290.22541186.v1
Autor:
Romel Somwar, Alexander Drilon, Marc Ladanyi, Eileen M. O'Reilly, Elisa de Stanchina, Ernesto Wasserman, Jeroen J. Lammerts van Bueren, Ron C.J. Schackmann, Cecile A.W. Geuijen, Marie N. O'Connor, Jim Ford, Jean Torrisi, Thrusha Chauhan, Sara H. Shameem, Morana Vojnic, Allan J.W. Lui, Marissa S. Mattar, Whitney J. Sisso, Inna Khodos, Madelyn Espinosa-Cotton, Igor Odintsov, Alison M. Schram
NRG1 rearrangements are recurrent oncogenic drivers in solid tumors. NRG1 binds to HER3, leading to heterodimerization with other HER/ERBB kinases, increased downstream signaling, and tumorigenesis. Targeting ERBBs, therefore, represents a therapeuti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29ad90ec0c5517efbc60698dfdb31aea
https://doi.org/10.1158/2159-8290.c.6549563.v1
https://doi.org/10.1158/2159-8290.c.6549563.v1
Autor:
Mrinal M. Gounder, Khashayarsha Khazaie, Mary Varterasian, Brent Kreider, David Tung, Alexey A. Leontovich, Saurabh Saha, Linping Zhang, Ronald L. Korn, Jennifer L. Salstrom, Maria Miller, Amanda Collins, Gary DeCrescenzo, Ernest Trevino, Alice Weissfeld, Stephen B. Solomon, Jean Torrisi, Anjali Raina, Divya Sakamuri, Steven Y. Huang, Mark Klang, Daniel D. Karp, Sarina A. Piha-Paul, David S. Hong, Tyler Masters, Thorunn Helgason, Dale R. Shepard, Andrea Wang-Gillam, Ravi Murthy, Sanjay Goel, Abdulmohammad Pezeshki, Halle Huihong Zhang, Filip Janku
Supplementary Figure 1. Of 16 patients (7 with and 9 without germination) with available data, 11 (69%) had a decrease in tumor density (-4% to -476%). The most robust decreases in density were observed in patients with germination. Supplementary Fig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c81284b48a4d230d3f1da9bd671c963
https://doi.org/10.1158/1078-0432.22478556
https://doi.org/10.1158/1078-0432.22478556
Autor:
Mrinal M. Gounder, Khashayarsha Khazaie, Mary Varterasian, Brent Kreider, David Tung, Alexey A. Leontovich, Saurabh Saha, Linping Zhang, Ronald L. Korn, Jennifer L. Salstrom, Maria Miller, Amanda Collins, Gary DeCrescenzo, Ernest Trevino, Alice Weissfeld, Stephen B. Solomon, Jean Torrisi, Anjali Raina, Divya Sakamuri, Steven Y. Huang, Mark Klang, Daniel D. Karp, Sarina A. Piha-Paul, David S. Hong, Tyler Masters, Thorunn Helgason, Dale R. Shepard, Andrea Wang-Gillam, Ravi Murthy, Sanjay Goel, Abdulmohammad Pezeshki, Halle Huihong Zhang, Filip Janku
Purpose:Intratumorally injected Clostridium novyi-NT (nontoxic; lacking the alpha toxin), an attenuated strain of C. novyi, replicates within hypoxic tumor regions resulting in tumor-confined cell lysis and inflammatory response in animals, which war
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ee8c35e7baa12ec727650c1b68bd0ce
https://doi.org/10.1158/1078-0432.c.6529983.v1
https://doi.org/10.1158/1078-0432.c.6529983.v1
Autor:
Mrinal M. Gounder, Khashayarsha Khazaie, Mary Varterasian, Brent Kreider, David Tung, Alexey A. Leontovich, Saurabh Saha, Linping Zhang, Ronald L. Korn, Jennifer L. Salstrom, Maria Miller, Amanda Collins, Gary DeCrescenzo, Ernest Trevino, Alice Weissfeld, Stephen B. Solomon, Jean Torrisi, Anjali Raina, Divya Sakamuri, Steven Y. Huang, Mark Klang, Daniel D. Karp, Sarina A. Piha-Paul, David S. Hong, Tyler Masters, Thorunn Helgason, Dale R. Shepard, Andrea Wang-Gillam, Ravi Murthy, Sanjay Goel, Abdulmohammad Pezeshki, Halle Huihong Zhang, Filip Janku
Supplementary Legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::354c39856fd9064a50cef4f72fd2f95a
https://doi.org/10.1158/1078-0432.22478550
https://doi.org/10.1158/1078-0432.22478550
Autor:
Alison M. Schram, Igor Odintsov, Madelyn Espinosa-Cotton, Inna Khodos, Whitney J. Sisso, Marissa S. Mattar, Allan J.W. Lui, Morana Vojnic, Sara H. Shameem, Thrusha Chauhan, Jean Torrisi, Jim Ford, Marie N. O'Connor, Cecile A.W. Geuijen, Ron C.J. Schackmann, Jeroen J. Lammerts van Bueren, Ernesto Wasserman, Elisa de Stanchina, Eileen M. O'Reilly, Marc Ladanyi, Alexander Drilon, Romel Somwar
Publikováno v:
Cancer Discov
NRG1 rearrangements are recurrent oncogenic drivers in solid tumors. NRG1 binds to HER3, leading to heterodimerization with other HER/ERBB kinases, increased downstream signaling, and tumorigenesis. Targeting ERBBs, therefore, represents a therapeuti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d95151a78f3149678f1573205c587eb3
https://doi.org/10.1158/2159-8290.cd-21-1119
https://doi.org/10.1158/2159-8290.cd-21-1119
Autor:
Andrea Wang-Gillam, Ernest Trevino, Sarina Anne Piha-Paul, Halle H. Zhang, Khashayarsha Khazaie, Amanda Collins, Tyler Masters, Mark Klang, Thorunn Helgason, Daniel D. Karp, Sanjay Goel, David Tung, Ronald L. Korn, Alexey A. Leontovich, Brent Kreider, Filip Janku, Mary Varterasian, Saurabh Saha, Divya Sakamuri, Maria Miller, David S. Hong, Anjali Raina, Jennifer L. Salstrom, Jean Torrisi, Decrescenzo Gary A, Alice S. Weissfeld, Linping Zhang, Dale R. Shepard, Abdul Mohammad Pezeshki, Stephen B. Solomon, Mrinal M. Gounder, Steven Y. Huang, Ravi Murthy
Publikováno v:
Clinical Cancer Research. 27:96-106
Purpose: Intratumorally injected Clostridium novyi-NT (nontoxic; lacking the alpha toxin), an attenuated strain of C. novyi, replicates within hypoxic tumor regions resulting in tumor-confined cell lysis and inflammatory response in animals, which wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::022f02290a6facded3246c3101a97367
https://doi.org/10.1158/1078-0432.ccr-20-2065
https://doi.org/10.1158/1078-0432.ccr-20-2065
Autor:
Helen Won, Carol Aghajanian, Catherine Zimel, Paul Sabbatini, Martee L. Hensley, Roisin E. O'Cearbhaill, Krysten Soldan, William P. Tew, Kenneth Seier, Rachel N. Grisham, Maria M. Rubinstein, Vicky Makker, S. Duygu Selcuklu, David M. Hyman, Joyce Guillen, Tiffany A. Troso-Sandoval, Imogen Caird, Alexia Iasonos, Jean Torrisi
Publikováno v:
Cancer
Background PI3K pathway activation is common in endometrial cancer. We evaluated the safety and efficacy of the dual PI3K/mTOR inhibitor, LY3023414, in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway. Meth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03b13643a2ad35fbafe9ffa6dd4f6d3f
https://doi.org/10.1002/cncr.32677
https://doi.org/10.1002/cncr.32677
Autor:
D. Welsch, David M. Hyman, Cecilia Lezcano, Mary Varterasian, Ryan J. Sullivan, Mario E. Lacouture, Bob T. Li, Michael Offin, Dazhi Liu, Jean Torrisi, S. Brownstein, A. Groover, James J. Harding, J. Wu, Mrinal M. Gounder, Alexander Drilon, Filip Janku, W. Abida
Publikováno v:
Invest New Drugs
Background Ulixertinib is the first-in-class ERK1/2 kinase inhibitor with encouraging clinical activity in BRAF- and NRAS-mutant cancers. Dermatologic adverse events (dAEs) are common with ulixertinib, so management guidelines like those established
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fabc6e04310ef81127bf8efc0e5c3664
https://europepmc.org/articles/PMC9282166/
https://europepmc.org/articles/PMC9282166/
Autor:
Filip, Janku, Halle Huihong, Zhang, Abdulmohammad, Pezeshki, Sanjay, Goel, Ravi, Murthy, Andrea, Wang-Gillam, Dale R, Shepard, Thorunn, Helgason, Tyler, Masters, David S, Hong, Sarina A, Piha-Paul, Daniel D, Karp, Mark, Klang, Steven Y, Huang, Divya, Sakamuri, Anjali, Raina, Jean, Torrisi, Stephen B, Solomon, Alice, Weissfeld, Ernest, Trevino, Gary, DeCrescenzo, Amanda, Collins, Maria, Miller, Jennifer L, Salstrom, Ronald L, Korn, Linping, Zhang, Saurabh, Saha, Alexey A, Leontovich, David, Tung, Brent, Kreider, Mary, Varterasian, Khashayarsha, Khazaie, Mrinal M, Gounder
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(1)
Intratumorally injectedThis first-in-human study (NCT01924689) enrolled patients with injectable, treatment-refractory solid tumors to receive a single intratumoral injection ofAmong 24 patients, a single intratumoral injection ofSingle intratumoral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0c30bd94fe50e24e6dc03247153acc93
https://pubmed.ncbi.nlm.nih.gov/33046513
https://pubmed.ncbi.nlm.nih.gov/33046513